The role of hypoxia-inducible factor-1 alpha in multidrug-resistant breast cancer

The role of hypoxia-inducible factor-1 alpha in multidrug-resistant breast cancer

Breast cancer is the most common cancer in women worldwide with increasing incidence. Significant therapeutics advances in the field of breast cancer have resulted in a growing number of treatment options, whereas de novo or acquired resistance is still a persistent clinical challenge. Drug resistan...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in oncology Vol. 12; p. 964934
Main Authors: Yong, Liyun, Tang, Shasha, Yu, Haixin, Zhang, Hongyi, Zhang, Yi, Wan, Yuan, Cai, Fengfeng
Format: Journal Article
Language:English
Published: Frontiers Media S.A 08-08-2022
Subjects:
breast cancer
drug
hypoxia inducible factor-1 Alpha (HIF-1α)
inhibition
Oncology
resistance
targeted drugs
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Breast cancer is the most common cancer in women worldwide with increasing incidence. Significant therapeutics advances in the field of breast cancer have resulted in a growing number of treatment options, whereas de novo or acquired resistance is still a persistent clinical challenge. Drug resistance involves a variety of mechanisms, and hypoxia is one of the many causes. Hypoxia-inducible Factor-1 Alpha (HIF-1α) is a key transcription factor which can regulate the response of cells to hypoxia. HIF-1α can trigger anaerobic glycolysis of tumor cells, induce angiogenesis, promote the proliferation, invasion, and migration of tumor cells, and lead to multidrug resistance. This review mainly discusses the role of HIF-1α in the drug-resistant breast cancer and highlighted the potential of HIF-1α -targeted therapy.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
These authors have contributed equally to this work
This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Oncology
Reviewed by: Mayank Kumar, University of Florida, United States; Ruby Sharma, Albert Einstein College of Medicine, United States
These authors have contributed equally to this work and share last authorship
Edited by: Subhadeep Roy, Indian Institute of Technology Delhi, India
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2022.964934